Ascentage Pharma Group International
HKEX:6855

Watchlist Manager
Ascentage Pharma Group International Logo
Ascentage Pharma Group International
HKEX:6855
Watchlist
Price: 41.3 HKD 0.49%
Market Cap: 12.9B HKD
Have any thoughts about
Ascentage Pharma Group International?
Write Note

Operating Margin
Ascentage Pharma Group International

-36.5%
Current
-1 207%
Average
-7.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-36.5%
=
Operating Profit
-329.9m
/
Revenue
903m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CN
Ascentage Pharma Group International
HKEX:6855
13B HKD
-37%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
311.8B USD
28%
US
Amgen Inc
NASDAQ:AMGN
149.6B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
114.1B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.9B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.3B EUR
-22%
Country CN
Market Cap 13B HKD
Operating Margin
-37%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 311.8B USD
Operating Margin
28%
Country US
Market Cap 149.6B USD
Operating Margin
19%
Country US
Market Cap 119.6B USD
Operating Margin
40%
Country US
Market Cap 114.1B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.9B AUD
Operating Margin
26%
Country US
Market Cap 82.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35.3B EUR
Operating Margin
-22%
No Stocks Found

Ascentage Pharma Group International
Glance View

Market Cap
13B HKD
Industry
Biotechnology

Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 613 full-time employees. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.

Intrinsic Value
58.55 HKD
Undervaluation 29%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-36.5%
=
Operating Profit
-329.9m
/
Revenue
903m
What is the Operating Margin of Ascentage Pharma Group International?

Based on Ascentage Pharma Group International's most recent financial statements, the company has Operating Margin of -36.5%.